Phaseline

Companies › Syndeio Biosciences

Syndeio Biosciences: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Other, Psychiatry; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Zelquistinel
Positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2DPhase 2Major Depressive Disorder; Healthy Volunteers in Fed and Fasted StateSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07099989ZelquistinelPhase 1Healthy Volunteers in Fed and Fasted StateOtherFeb 2026
NCT06547489ZelquistinelPhase 2Major Depressive DisorderPsychiatrySep 2027
NCT07115329ZelquistinelPhase 2Major Depressive DisorderPsychiatryMar 2028

Targets

GRIN1 (1) GRIN2A (1) GRIN2B (1) GRIN2C (1) GRIN2D (1)

Companies with the same targets

SHINKEI Therapeutics Johnson & Johnson (Janssen) Aptinyx GRIN Therapeutics Praxis Precision Medicines Arialys Australia atai Therapeutics Exciva CSPC Ouyi Pharmaceutical Neuren Pharmaceuticals

Companies built like this

SyneuRx International (Taiwan) Arialys Australia atai Therapeutics Neuren Pharmaceuticals Clear Scientific

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.